Difference between revisions of "Bevacizumab (Avastin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(updated content)
m (categories)
Line 29: Line 29:
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drug index]]
 +
[[Category:Chemotherapy]]
 +
[[Category:Antibody medications]]
 +
[[Category:VEGF inhibitors]]
 +
[[Category:Breast cancer medications]]
 +
[[Category:Cervical cancer medications]]
 +
[[Category:Colon cancer medications]]
 +
[[Category:Esophageal cancer medications]]
 +
[[Category:Hepatobiliary cancer medications]]
 +
[[Category:Non-small cell lung cancer medications]]
 +
[[Category:Ovarian cancer medications]]
 +
[[Category:Renal cancer medications]]
 +
[[Category:Cancer of unknown primary medications]]

Revision as of 01:37, 8 October 2012

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Information about counterfeit Bevacizumab (Avastin)

Patient drug information

References